Oscotec Inc. (KOSDAQ:039200)
South Korea · Delayed Price · Currency is KRW 37,000
+550 (1.51%)
Jun 23, 2026, 3:30 PM KST
Oscotec Revenue
Oscotec had revenue of 3.65B KRW in the quarter ending March 31, 2026, with 88.40% growth. This brings the company's revenue in the last twelve months to 101.55B, up 191.13% year-over-year. In the year 2025, Oscotec had annual revenue of 99.84B with 193.58% growth.
Revenue (ttm)
101.55B
Revenue Growth
+191.13%
P/S Ratio
13.73
Revenue / Employee
1.85B
Employees
55
Market Cap
1.39T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 99.84B | 65.83B | 193.58% |
| Dec 31, 2024 | 34.01B | 29.06B | 586.89% |
| Dec 31, 2023 | 4.95B | -111.45M | -2.20% |
| Dec 31, 2022 | 5.06B | 1.16B | 29.71% |
| Dec 31, 2021 | 3.90B | -39.57B | -91.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| GC Biopharma | 2.04T |
| Daewoong Pharmaceutical | 1.59T |
| Samsung Epis Holdings | 1.51T |
| HK inno.N | 839.63B |
| Seegene | 487.37B |
| ALTEOGEN | 203.76B |
Oscotec News
- 21 days ago - Agios Enters Global License Agreement For Cevidoplenib - Nasdaq